Hitting the Sweet Spot: The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis
Open Access
- 1 October 2025
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (10) , 1896-1897
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Insulin for early glycaemic abnormality in children with cystic fibrosis without cystic fibrosis-related diabetes (CF-IDEA): a randomised controlled trialThe Lancet Child & Adolescent Health, 2025
- Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosisThorax, 2023
- The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetesJournal of Clinical & Translational Endocrinology, 2022
- Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et alJournal of Cystic Fibrosis, 2020
- Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosisJournal of Cystic Fibrosis, 2019
- The impact of cystic fibrosis-related diabetes on health-related quality of lifeJournal of Cystic Fibrosis, 2019
- Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftorThorax, 2018
- Abnormal Glucose Tolerance in Infants and Young Children with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Diabetes-related Mortality in Adults with Cystic Fibrosis. Role of Genotype and SexAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot studyPediatric Diabetes, 2013